PT-141 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-29. Numbers and descriptions here follow the published literature rather than marketing material.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
| Property | Value | Notes |
|---|---|---|
| Primary target | MC4R | Highest reported functional activity |
| Peak plasma time | About 1 hour | Subcutaneous administration |
| Elimination half-life | A few hours | Active fragment may extend effect |
| Main clearance route | Proteolytic degradation | Not cytochrome-dependent |
| Typical assay | LC-MS/MS | Plasma quantification |
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Diseases of the skin include skin infections and skin neoplasms (including skin cancer). Dermatology is the branch of medicine that deals with conditions of the skin. There are seven cervical, twelve thoracic, five lumbar, and five sacral. Certain diseases like shingles, caused by varicella-zoster infection, have pain sensations and eruptive rashes involving dermatomal distribution. Dermatomes are helpful in the diagnosis of vertebral spinal injury levels. Aside from the dermatomes, the epidermis cells are susceptible to neoplastic changes, resulting in various cancer types. The skin is also valuable for diagnosis of other conditions, since many medical signs show through the skin. Skin colour affects the visibility of these signs, a source of misdiagnosis in unaware medical personnel.
== Medical uses == Suzetrigine is indicated for the treatment of moderate to severe acute pain in adults. It was primarily studied in people with postoperative pain, including due to abdominoplasty and bunionectomy. However, a small minority of patients received suzetrigine for non-surgical pain, including arthralgias, limb pain, and sprains and strains. Treatment of acute pain using suzetrigine has not been studied beyond 14 days of use. In clinical studies conducted through 2024, suzetrigine reduced pain typically from 7 to 4 on the standard numeric scale used to rate pain. The efficacy of suzetrigine was evaluated in two randomized, double-blind, placebo- and active-controlled trials of acute surgical pain, one following abdominoplasty and the other following bunionectomy. Both trials found that suzetrigine reduced pain more effectively than placebo. Suzetrigine was not superior to placebo for the treatment of lumbosacral radiculopathy. However, in clinical studies, no superiority over hydrocodone and paracetamol (acetaminophen) in terms of pain reduction was shown over 48 hours. Medical professionals have noted its efficacy may be inferior to high-dose opioid analgesics. There are no studies comparing suzetrigine with high-dose opioids. Suzetrigine exhibits CYP3A4-mediated drug interactions and there is limited long-term data regarding its use. Moreover, usage has not been studied in those younger than 18 or older than 80 years of age and its cost-effectiveness is disputed.
== Career == Macor began his industrial career at Pfizer in 1986, where he was a co-inventor of eletriptan, a triptan marketed as Relpax for the acute treatment of migraine. Eletriptan was approved by the FDA in 2002. He later joined Bristol-Myers Squibb in 1997, where he served as executive director of neuroscience chemistry. At Bristol-Myers Squibb, he was a co-inventor in the program that produced the CGRP receptor antagonists rimegepant and zavegepant, which were subsequently developed by Biohaven Pharmaceuticals and approved by the FDA in 2020 and 2023, respectively, for the treatment of migraine. He is also a co-inventor of sparsentan, a dual endothelin and angiotensin II receptor antagonist developed by Travere Therapeutics and approved by the FDA in 2023 for the reduction of proteinuria in adults with IgA nephropathy. Macor’s work at Bristol-Myers Squibb also included the company’s Alzheimer’s disease program, where he contributed to the discovery of avagacestat (BMS-708163), a γ-secretase inhibitor that advanced to Phase 2 clinical trials before development was discontinued. Macor is an author on more than 220 peer-reviewed publications and a named inventor on 150 issued U.S. patents.
==== Oily skin ==== Oily skin is caused by over-active sebaceous glands, that produce a substance called sebum, a naturally healthy skin lubricant. A high glycemic-index diet and dairy products (except for cheese) consumption increase IGF-1 generation, which in turn increases sebum production. Overwashing the skin does not cause sebum overproduction but may cause dryness. When the skin produces excessive sebum, it becomes heavy and thick in texture, known as oily skin. Oily skin is typified by shininess, blemishes and pimples. The oily-skin type is not necessarily bad, since such skin is less prone to wrinkling, or other signs of ageing, because the oil helps to keep needed moisture locked into the epidermis (outermost layer of skin). The negative aspect of the oily-skin type is that oily complexions are especially susceptible to clogged pores, blackheads, and buildup of dead skin cells on the surface of the skin. Oily skin can be sallow and rough in texture and tends to have large, clearly visible pores everywhere, except around the eyes and neck.
Sources: en.wikipedia.org
Echinoderms differ from chordates and their other relatives in three conspicuous ways: they possess bilateral symmetry only as larvae – in adulthood they have radial symmetry, meaning that their body pattern is shaped like a wheel; they have tube feet; and their bodies are supported by dermal skeletons made of calcite, a material not used by chordates. Their hard, calcified shells keep their bodies well protected from the environment, and these skeletons enclose their bodies, but are also covered by thin skins. The feet are powered by another unique feature of echinoderms, a water vascular system of canals that also functions as a "lung" and surrounded by muscles that act as pumps. Crinoids are typically sessile and look rather like flowers (hence the common name "sea lilies"), and use their feather-like arms to filter food particles out of the water; most live anchored to rocks, but a few species can move very slowly. Other echinoderms are mobile and take a variety of body shapes, for example starfish and brittle stars, sea urchins and sea cucumbers.
=== iDP === Internal DisplayPort (iDP) is a standard that defines an internal link between a digital TV system on a chip controller and the display panel's timing controller. Version 1.0 was approved in April 2010. It aims to replace currently used internal FPD-Link lanes with a DisplayPort connection. iDP features a unique physical interface and protocols, which are not directly compatible with DisplayPort and are not applicable to external connection, however they enable very high resolution and refresh rates while providing simplicity and extensibility. iDP features a non-variable 2.7 GHz clock and is nominally rated at 3.24 Gbit/s per lane, with up to sixteen lanes in a bank, resulting in a six-fold decrease in wiring requirements over FPD-Link for a 1080p24 signal; other data rates are also possible. iDP was built with simplicity in mind so doesn't have an AUX channel, content protection, or multiple streams; it does however have frame sequential and line interleaved stereo 3D.
Vi capsular polysaccharide vaccine (ViCPS) against typhoid caused by the Typhi serotype of Salmonella enterica. Instead of being a protein, the Vi antigen is a bacterial capsule polysacchide, made up of a long sugar chain linked to a lipid. Capsular vaccines like ViCPS tend to be weak at eliciting immune responses in children. Making a conjugate vaccine by linking the polysacchide with a toxoid increases the efficacy.
Unlike previous elections, healthcare reform played a much more minor role in the 2024 presidential election. Harris stated that she no longer supported a single-payer healthcare system as she had in 2020. Instead, she said she intended to protect and expand items legislated during the Obama and Biden administrations. She said she would "maintain and grow" the Affordable Care Act, while Trump said that he would replace it with his own healthcare plan. Harris also supported limiting yearly out-of-pocket drug costs for seniors, and expanding the $35 cap on insulin for seniors on Medicare to younger individuals in the program as well. Generally, both candidates supported using the government to rein in prescription drug costs. Trump suggested he was open to cutting entitlement programs, such as Social Security and Medicare, part of an effort to "[cut] waste" as described by his campaign. During his first term, several budget proposals did suggest cuts to the programs. Additionally, Vance and Speaker of the House Mike Johnson suggested cuts to the ACA, including around pre-existing conditions, were part of Trump's plan. After Robert F. Kennedy Jr. dropped out of the race and endorsed Trump, Kennedy advocated for his "Make America Healthy Again" agenda, pledging to combat the upward trend in chronic disease patients, with Trump saying Kennedy would "go wild" regarding policy on food and medicines.
=== IGF-1 === In December 2012, topical application of IGF-1 in a liposomal vehicle led to thicker and more rapid hair growth in transgenic mice with androgenic alopecia. The study did not show measurable systemic levels or hematopoietic side effects, suggesting potential for use in humans. Low energy radiofrequency irradiation induces IGF-1 in cultured human dermal papilla cells. Adenosine stimulates dermal papillae in vitro to induce IGF-1, along with fibroblast growth factors FGF7, FGF-2 and VEGF. β-catenin transcription increased, which promotes dermal papillae as well. Dietary isoflavones increase IGF production in scalp dermal papillae in transgenic mice. Topical capsaicin also stimulates IGF at hair follicles via release of vanilloid receptor-1, which in turn leads to more CGRP. Ascorbic acid has led to increased IGF expression in vitro.
Sources: en.wikipedia.org
What a terrible shame. It would be easy for me to get in a back room with this man's lawyer and make this go away, but there are some moments in life when you have to stand up and defend your honor against the evil in this world. I will not tolerate this heartless attempt to exploit me or the woman I loved. Cat's troubles were born long before I met her and sadly her tragic end was beyond anyone's control. I really hope that some day soon people will stop trying to profit from this and let her rest in peace. In October 2016, White's mother, Brigid Sweetman, also filed a wrongful death lawsuit against Carrey. Both lawsuits were dismissed on January 25, 2018, and attorneys for both sides confirmed there would be no further legal proceedings.
== In bacteria == All bacteria use proteolipids, sometimes confusingly referred to as bacterial lipoproteins, in their cell membrane. A common modification consists of N-acyl- and S‑diacylglycerol attached to an N-terminal cystine residue. Braun's lipoprotein, found in gram-negative bacteria, is a representative of this group. In addition, Mycobacterium O-mycolate proteins destined for the outer membrane. The plant chloroplast is capable of many of the same modifications that bacteria perform to proteolipids. One database for such N-Acyl Diacyl Glycerylated cell wall proteolipids is DOLOP. Pathogenic spirochetes, including Borrelia burgdorferi and Treponema pallidum, use their proteolipid adhesins to stick to victim cells. These proteins are also potent antigens, and are in fact the main immunogens of these two species. Proteolipids include bacterial antibiotics that are not synthesised in the ribosome. Products of nonribosomal peptide synthase may also involve a peptide structure linked to lipids. These are usually referred to as "lipopeptides". Bacterial "lipoproteins" and "lipopeptides" (LP) are potent inducers of sepsis, second only to lipopolysaccharide (LPS) in its ability to cause an inflammation response. While LPS is detected by the toll-like receptor TLR4, LPs are detected by TLR2.
== History == The Inner London Education Authority was established when the Greater London Council (GLC) replaced the London County Council (LCC) as the principal local authority for London in 1965. The LCC had, in 1904, taken over from the London School Board responsibility for education in Inner London. In what was to become Outer London, education was during the first half of the twentieth century primarily administered by the relevant county councils and county boroughs, with some functions delegated to second-tier councils in the area. The Herbert Commission report in 1960 recommended the establishment of the Greater London Council. It advocated a London-wide division of educational powers between the GLC and the London boroughs. The GLC would be responsible for strategic control of schools, and the boroughs for routine management. This part of the report was rejected by the government. Councils in the future Outer London area wanted greater control over education, preventing the creation of a London-wide local education authority (LEA), and there was strong opposition from teachers and other bodies to the idea of dividing up the LCC LEA. The London Government Act 1963 therefore created the ILEA to inherit the educational responsibilities of the LCC, and gave Outer London boroughs LEA status. The ILEA was originally conceived as a provisional body whose status would be reviewed before 1970, but the Labour government made its status permanent in 1965. The ILEA did not cover the small area of North Woolwich, where the LCC had provided a secondary school.
== Education == Primary schools in the town are: Buttsbury, Brightside, Sunnymede and South Green. There are two secondary comprehensives: Billericay School and Mayflower High School. St John's School in an independent school for children up to the age of 18.
Sources: en.wikipedia.org
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.
Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.
Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.